Treatment with low doses of interferon α (IFN-α) is now used as adjuvant therapy only in cases of ulcerated or stage IIB and IIC melanoma, for which new-generation adjuvant therapies (target therapy and/or immunotherapy) are not approved. This evidence concerns the gene IFNA2 and melanoma.